Bay Street News, January 2nd, 2024

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract […]

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company […]

CARLSBAD, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — AppTech Payments Corp. (Nasdaq: APCX) (“AppTech” or the “Company”), a pioneering Fintech company […]

Trogarzo®IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission comes […]

Not for distribution to United States news wire services or for dissemination in the United States TORONTO, Jan. 02, 2024 […]

MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) — Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash […]

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing […]

DURHAM, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced […]

SAN MATEO, Calif. and SINGAPORE, Jan. 02, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company […]

– Increases hashrate 44% YOY to 6.5 EH/s at Dec. 31, 2023, exceeding guidance –– Expands total contracted capacity to […]